Attention Deficit Hyperactivity Disorder Therapeutics Market 2023 Global Analysis, Growth, Size, Share, Trends, Forecast

Worldwide revenue from the interventional pulmonology market stands at US$ 1.2 Bn in 2022, with the global market estimated to surge ahead at a CAGR of 4.2% to reach a valuation of US$ 1.9 Bn by the end of 2033.

Get Free Sample Copy@ https://www.persistencemarketresearch.com/samples/4222

Both, stimulants and non-stimulants are gaining significant demand for the treatment of attention-deficit hyperactivity disorder. ADHD is one of the most common childhood disorders, and is more prevalent in males than females. ADHD is a chronic condition where treatment cannot cure the patient; however, early diagnosis and treatment could mitigate the symptoms. There are many effective ADHD therapeutics available, such as stimulants, amphetamine, and methylphenidate, which are generally selected by physicians for first medication. Besides, manufacturers are also continuously focusing on the development of new ADHD therapeutics with a diversity of mechanisms and functions.

Key Segments Covered in Attention Deficit Hyperactivity Disorder Therapeutics Industry Research

Drug:

• Stimulants
• Amphetamine
• Methylphenidate
• Dextroamphetamine
• Dexmethylphenidate
• Lisdexamfetamine Dimesylate
• Non-stimulants
• Atomoxetine
• Bupropion
• Guanfacine
• Clonidine

Age Group:

• Pediatric and Adolescent
• Adults

Distribution Channel:

• Specialty Clinics
• Hospital Pharmacies
• Retail Pharmacies
• E-Commerce

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

 Switch Over To The “Methodology” Tab@ https://www.persistencemarketresearch.com/methodology/31378

Competition Landscape

Manufacturers hope to expand their respective market shares by developing novel ADHD drugs at reduced prices.

To cut their manufacturing costs and compete in the market with lower pricing, the corporations are concentrating on outsourcing the production of ADHD medications to the Asian region. Companies gain product portfolio augmentation through mergers and acquisition activities.

Moreover, companies are engaging in mergers and acquisitions to increase their product offerings and global market presence.

Some key instances of development include:

• Japan granted approval for the use of UCB's Vimpat® (lacosamide) in January 2019 to treat partial-onset seizures in children aged 4 and older.
• Pfizer Inc. purchased Array, a biopharmaceutical firm specialising in the discovery and marketing of small molecule drugs, in July 2019.

Introduction of Innovative Drugs: Key Strategy of Leading Manufacturers

Manufacturers of generic drug are focusing on the introduction of cheaper and effective generic ADHD drugs to increase their market share. These generic drugs can cost several times lower than branded drugs, are equally safe, and of good quality and performance. Therefore, leaders in the global attention-deficit hyperactivity disorder therapeutics market are now looking forward to developing more generic drugs instead of branded ADHD drugs at a high cost. For instance, in March 2019, ANI Pharmaceuticals, Inc. announced the launch of 18mg and 27mg methylphenidate hydrochloride extended-release tablets for the treatment of ADHD.

Go To Purchase Now@ https://www.persistencemarketresearch.com/checkout/31378

More Valuable Insights on ADHD Therapeutics Market

Persistence Market Research offers a unique perspective and actionable insights on the attention-deficit hyperactivity disorder therapeutics market in its latest study, presenting historical demand assessment of 2015–2019 and projections for 2020–2030, on the basis of drug type (stimulants and non-stimulants), age group (pediatric & adolescents and adults), and distribution channel (hospital pharmacies, speciality clinics, retail pharmacies, and e-Commerce), across five major regions.